欧盟 - 保加利亚文 - EMA (European Medicines Agency)

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - Полови хормони и слиза на половата система, - Устна контрацепция. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - Антианемични препарати - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Антинеопластични средства - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - Множествена миелома - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - Имуносупресори - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - Множествена миелома - Антинеопластични средства - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - Множествена миелома - Антинеопластични средства - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

acino pharma gmbh - клопидогрел - peripheral vascular diseases; stroke; myocardial infarction - Антитромботични агенти - Клопидогрел е показан при възрастни за предпазване от атеротромботични инциденти при: * пациенти, страдащи от миокарден инфаркт (от няколко дни до 35 дни), исхемичен инсулт (от 7 дни до по-малко от 6 месеца) или установено периферно артериална болест. За повече информация, моля, вижте раздел 5.

欧盟 - 保加利亚文 - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - Антинеопластични средства - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.